ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: To date, limited research has been reported apart from BAY-293, a SOS1/RAS inhibitor, which is documented to enhance imatinib sensitivity and impede the proliferation of BCR–ABL–independent TKI-resistant CML cells (33).